Chris Spivey

Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.

In this episode of Drug Digest, Pharmaceutical Technology editors discuss the advantages and savings that continuous manufacturing may offer as well as the very real obstacles that might make a fully continuous process not feasible, especially in biologics manufacturing.

Vibha Jawa, executive director at Bristol Myers Squibb, discusses foreign epitopes recognition from what should be fully human antibody therapies.

Bob Girton, partner at Edgewater, discusses best practices for how pharma manufactures should incorporate sustainability into their operations.

Actions combatting the next pandemic must be diverse, reliable, and sustainable.

Nicole Lewis, PVP Program Manager at Boston Children's Hospital, discusses the science behind precision vaccines, a form of personalized vaccines.

Marcel Baumann, business development director at Recipharm, discusses soft mist inhaler technology from the show floor at the World Vaccine Conference.

Limitations in production platforms have impeded continuous manufacturing for advanced therapies.

What can we take away from Pfifzer's acquisition of Seagen?

Decreasing vein to vein time saves lives.

The further we pursue CGT, the more variability we need to account for in order to engineer consistency into these new products.

This new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns.

Public relations agencies dissect pharmaceutical trends: Brandwidth Solutions, Orientation Marketing and White Matter Communications

This compilation allows readers to adjust their thinking to appreciate the full impact certain select technologies will make on the industry by 2026.

Coverage of COVID-19 vaccines was surprisingly displaced by this year’s astounding oncology and iconoclastic gene therapy “cures.”

Logan Instruments discuses diffusion cell testing and what sets their company apart from other manufacturers.

Anthony Carpanzano, Director of R&D at JRS Pharma, discussed ongoing formulation challenges and trends.

In this episode of the Drug Solutions Podcast, Chris Spivey interviews executives at Shabas Solutions LLC, who ran the overseas QMM pilot project.

Overall industry growth conceals growing numbers of smaller, faster-paced, adaptable corporate structures.

mRNA may not be a train we necessarily all need to get onboard immediately, but we should know where the central train station is located, and what it connects us to.

Allison Labriola, Senior Technical Sales Representative, at JRS Pharma is interviewed by the Editorial Director of Pharmaceutical Technology Chris Spivey about how the food industry is affecting the pharmaceutical industry.

This video is an interview with Jon Brice, Vice President of Business Development at Asymchem at the AAPS Conference in Boston, Massachusetts.

Content is king in publishing, but interpretation is imperator.

One can only learn the secrets of "fight club" by attending its meetings.

How Pfizer’s external-facing research and development scientists uncover the most promising emerging therapy concepts and ideas in the pharmaceutical landscape.

Creating building blocks for good manufacturing practices is essential.

The flow of capital and scientific acuity irrigates this pharm system.

More than anything else MonkeyPox and COVID-19 have shown that we are interdependent, no matter what continent you call home.

Promising applications for targeted delivery may be cresting the horizon.

As we reach further afield in the molecular universe, we encounter new types of problems to resolve.